Gross Margin Expansion of 79 Basis Points
Adjusted EPS Growth of Nearly Four Times with GAAP EPS Loss of $ and Adjusted EPS of $0.19
Investments Outlined at 2023 Investor Day for Long-Term Growth.
Top Line Expansion Led by Healthy Demand in Patient Direct and Medical Distribution
Operating Cash Flow Generation Supported $188 million in Total Debt Reduction
.